	US 12,221,416 B2
	Antagonists of human integrin α4β7
Matthew G. Bursavich, Needham, MA (US); Dawn M. Troast, Bedford, MA (US); Bryce A. Harrison, Framingham, MA (US); Blaise S. Lippa, Newton, MA (US); Bruce N. Rogers, Belmont, MA (US); Kyle D. Konze, Brooklyn, NY (US); Aleksey I. Gerasyuto, Flemington, NY (US); Tyler Day, New York, NY (US); Fu-Yang Lin, Sudbury, MA (US); Kristopher N. Hahn, Medford, MA (US); Mats A. Svensson, New York, NY (US); Byungchan Kim, West New York, NY (US); Cheng Zhong, Belmont, MA (US); Alexey A. Lugovskoy, Belmont, MA (US); and Brian Sosa, Cambridge, MA (US)
Assigned to Morphic Therapeutic, Inc., Waltham, MA (US)
Filed by Morphic Therapeutic, Inc., Waltham, MA (US)
Filed on Dec. 22, 2023, as Appl. No. 18/394,421.
Application 18/394,421 is a continuation of application No. 17/525,479, filed on Nov. 12, 2021, abandoned.
Application 17/525,479 is a continuation of application No. 16/939,812, filed on Jul. 27, 2020, granted, now 11,174,228, issued on Nov. 16, 2021.
Application 16/939,812 is a continuation of application No. 16/382,512, filed on Apr. 12, 2019, granted, now 10,759,756, issued on Sep. 1, 2020.
Claims priority of provisional application 62/656,742, filed on Apr. 12, 2018.
Prior Publication US 2024/0294475 A1, Sep. 5, 2024
Int. Cl. C07D 401/06 (2006.01); C07D 205/08 (2006.01); C07D 213/64 (2006.01); C07D 237/32 (2006.01); C07D 239/72 (2006.01); C07D 239/90 (2006.01); C07D 241/18 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01)

CPC C07D 213/64 (2013.01) [C07D 205/08 (2013.01); C07D 237/32 (2013.01); C07D 239/90 (2013.01); C07D 241/18 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01)]

20 Claims

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.